Accuracy of ICD Influenza Discharge Diagnosis Codes in Hospitalized Adults From the Valencia Region, Spain, in the Pre-COVID-19 Period 2012/2013 to 2017/2018

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Mira-Iglesias, Ainara
  • Lopez-Lacort, Monica
  • Bricout, Helene
  • Loiacono, Matthew
  • Carballido-Fernandez, Mario
  • Mollar-Maseres, Joan
  • Schwarz-Chavarri, German
  • Lopez-Labrador, F. Xavier
  • Puig-Barbera, Joan
  • Diez-Domingo, Javier
  • Orrico-Sanchez, Alejandro

Grups d'Investigació

Abstract

BackgroundInternational Classification of Diseases (ICD) codes obtained from real-world data can be used to identify influenza cases for epidemiological research but, without validation, may introduce biases. The objective of this study was to validate ICD influenza discharge diagnoses using real-time reverse transcription-polymerase chain reaction (RT-PCR) laboratory-confirmed influenza (LCI) results.MethodsThe study was conducted during six influenza seasons (2012/2013-2017/2018) in the Valencia Hospital Surveillance Network for the Study of Influenza (VAHNSI). Patients aged 18+ years were identified via active-surveillance and had to meet an influenza-like illness (ILI) case definition to be included. All patients were tested for influenza by real-time RT-PCR. Main and secondary influenza discharge diagnosis codes were extracted from hospital discharge letters. Positive predictive values (PPVs) and the complementary of the sensitivities (1-Sensitivity) of ICD codes with corresponding 95% credible intervals (CrIs) were estimated via binomial Bayesian regression models.ResultsA total of 13,545 patients were included, with 2257 (17%) positive for influenza. Of 2257 LCI cases, 1385 (61%) were not ICD-coded as influenza. Overall, 74.73% (95% CrI: 63.24-84.44) of LCI were not-ICD coded as influenza (1-Sensitivity) after adjustment. Sensitivity improved across seasons and with increasing age. Average PPV was 74.02% (95% CrI: 68.58-79.17), ranging from 43.71% to 81.57% between seasons.ConclusionUsing only main and secondary discharge diagnosis codes for influenza detection markedly underestimates the full burden of influenza in hospitalized patients. Future studies, including post-COVID context, using prospective surveillance for ILI are required to assess the validity of hospital discharge data as a tool for determining influenza-related burden of disease.

Dades de la publicació

ISSN/ISSNe:
1750-2640, 1750-2659

INFLUENZA AND OTHER RESPIRATORY VIRUSES  Blackwell Publishing Inc.

Tipus:
Article
Pàgines:
-
PubMed:
39909969
Factor d'Impacte:
1,637 SCImago
Quartil:
Q1 SCImago

Documents

  • No hi ha documents

Mètriques

Filiacions

Filiacions no disponibles

Projectes associats

Identificación de biomarcadores inmunológicos en pacientes alérgicos.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

LET-INM-2020 . 2023

Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a Dermatophagoides pteronyssinus y/o Dermatophagoides farinae.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

MM09-SIT-023 . 2023

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA).

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

D3250C00024 . 2023

Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea (Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del polvo en pacientes con rinitis/rinoconjuntivitis alérgica.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

2023

Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad a largo plazo de dupilumab en niños de 2 a <6 años con asma no controlada y/o sibilancias asmáticas graves recurrentes.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

EFC14771 . 2024

Estudio fase III multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo de la eficacia y la seguridad de tezepelumab en niños de 5 a <12 años con asma grave no controlada (HORIZON).

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

D5180C00016 . 2024

Estudio epidemiológico de las enfermedades alérgicas pediátricas en España.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

ALERGOPEDIÁTRICA 2020 . 2024

Compartir la publicació